ClinicalTrials.gg
Not yet recruitingNCT07297069Updated Dec 24, 2025

Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial

A Phase 2 interventional study of Infliximab and Tofacitinib in Acute Severe Ulcerative Colitis, sponsored by Asian Institute of Gastroenterology, India. Not yet recruiting at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Asian Institute of Gastroenterology, India · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing infliximab in Colitis, Ulcerative — 7 open to participants now, 9 under way, 2 of them phase 3. Infliximab · Colitis, Ulcerative.

Planned enrollment
16th of 26
60 · median 78
Started
2026
the only one that year
Phase 2
2 of 26
2 open now
Registered
26th of 26
by date
Lead sponsor
1 of 26
Asian Institute of Gastroenterology, India

Among the 26 studies testing infliximab in Colitis, Ulcerative, this one is the 16th largest by planned enrollment, is the only one that started in 2026, is one of 2 in phase 2, and was the 26th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

7 of the 26 studies testing infliximab in Colitis, Ulcerative are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About infliximab

Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing infliximab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

In adults hospitalized with acute severe ulcerative colitis who fail to respond to intravenous steroids, does treatment with a combination of infliximab and tofacitinib, compared with infliximab alone or tofacitinib alone, result in higher rates of early clinical remission and mucosal healing, and fewer treatment-related complications over a 10 week period

Read the detailed description

Acute severe ulcerative colitis (ASUC) is a life threatening manifestation of ulcerative colitis that requires urgent medical treatment and hospitalization. Despite the use of rapid induction intravenous corticosteroids, some patients fail to respond and require rescue therapy. Infliximab is commonly used as rescue treatment; however, its effectiveness may be reduced in patients with severe inflammation and hypoalbuminemia. As a result, colectomy rates for ASUC remain significant and improved early rescue strategies are needed.

Tofacitinib is an oral Janus kinase inhibitor that targets multiple cytokine pathways involved in ulcerative colitis. It has a rapid onset of action and has shown benefit in severe and steroid-refractory disease. Because infliximab and tofacitinib act on different immunologic targets, their combined use may provide complementary therapeutic effects. Emerging observational data suggest that combining a biologic agent with a small-molecule therapy may be safe and potentially more effective in patients with severe disease who are at high risk for treatment failure.

This study is designed to explore whether the combination of infliximab and tofacitinib offers greater early clinical benefit compared to infliximab alone, tofacitinib alone for adults hospitalized with ASUC who do not respond to intravenous corticosteroids.The goal is to generate preliminary data that may inform future treatment approaches aimed at improving remission rates, accelerating mucosal healing, and reducing the need for colectomy in this high risk population.

03

Conditions studied

  • Acute Severe Ulcerative Colitis

Browse trials for

Keywords

  • Rescue therapy
  • Combination therapy
  • Steroid refractory ulcerative colitis
  • Infliximab
  • Tofacitinib
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult (aged 18 years to 65 years) patients hospitalised due to ASUC

Exclusion criteria

Exclusion Criteria:

  1. Patients with UC who did not meet the Truelove Witts criteria for ASUC.
  2. Patients who are already on Tofacitinib / Infliximab.
  3. Latent or active tuberculosis.
  4. Crohn's or Indeterminate colitis.
  5. Mega colon (if the diameter of the transverse colon is 5.5 cm or more, with apparent oedema of the bowel wall on plain abdominal radiographs).
  6. Pseudomembranous colitis or concomitant CMV colitis.
  7. Intestinal perforation.
  8. Massive haemorrhage requiring emergency colectomy.
  9. Pregnant or lactating female individuals.
  10. Current diagnosis or history of thromboembolic disease patients with severe cardiorespiratory, renal or hepatic Co morbidities.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Infliximab Plus Tofacitinib

    Participants with acute severe ulcerative colitis who do not respond to intravenous corticosteroids will receive combination therapy with infliximab and tofacitinib. Infliximab 300 mg will be given intravenously, and tofacitinib will be administered orally at 10 mg twice daily. This arm evaluates whether combination therapy produces enhanced early clinical improvement and offers greater effectiveness and safety in inducing early clinical remission and mucosal healing compared with either agent alone.

    Drug: Infliximab · Drug: Tofacitinib

  • Active comparator
    Infliximab Only

    Participants with acute severe ulcerative colitis who do not respond to intravenous corticosteroids will receive infliximab alone as rescue therapy. Infliximab will be administered at a dose of 300 mg intravenously according to protocol. This arm evaluates the effectiveness and safety of infliximab monotherapy in inducing early clinical remission and mucosal healing.

    Drug: Infliximab

  • Active comparator
    Tofacitinib Only

    Participants with acute severe ulcerative colitis who do not respond to intravenous corticosteroids will receive tofacitinib alone as rescue therapy. Tofacitinib will be administered orally at 10 mg twice daily. This arm assesses the effectiveness and safety of tofacitinib monotherapy in inducing early clinical remission and mucosal healing.

    Drug: Tofacitinib

Interventions

  • Participants with acute severe ulcerative colitis who do not respond to intravenous corticosteroids will receive infliximab as rescue therapy. Infliximab 300 mg will be administered intravenously. This arm evaluates the effectiveness and safety of infliximab monotherapy in inducing early clinical remission and mucosal healing.

  • Participants with acute severe ulcerative colitis who do not respond to intravenous corticosteroids will receive tofacitinib as rescue therapy. Tofacitinib will be administered orally at 10 mg twice daily. This arm assesses the effectiveness and safety of tofacitinib monotherapy in inducing early clinical remission and mucosal healing.

06

What researchers measure

Primary outcomes

  1. Clinical Remission Rate

    Clinical remission is defined as defined as a Mayo score ≤2 and no individual subscore \>1.Participants meeting these criteria will be classified as achieving clinical remission.

    Time frame: Week 1 and Week 4

Secondary outcomes

  1. Clinical Response Rate

    Reduction of baseline Mayo score by ≥3 points and a decrease of 30% from the baseline score with a decrease of at least one point on the rectal bleeding subscale or an absolute rectal bleeding score of 0 or 1.

    Time frame: Week 1 and Week 4

  2. Mucosal Healing Rate

    Mucosal healing is defined as an endoscopic Mayo score of 0 or 1 on flexible sigmoidoscopy. Participants undergoing endoscopic evaluation who meet these criteria will be classified as achieving mucosal healing.

    Time frame: Week 4 and Week 12

  3. Treatment Related Adverse Events

    Adverse events related to study medications, including but not limited to infections, lymphocytopenia, thromboembolic events, hyperlipidemia, and infusion or drug-related reactions, will be recorded throughout the study period. Severity and relationship to the study intervention will be assessed.

    Time frame: Baseline through Week 12

07

Study locations

1 site
08

References and documents

Publications

  • Hickman K, Jordan R, Sonnier W. Combination biologic and small molecule therapy for refractory ulcerative colitis. Gastroenterology. 2022;162(3 Suppl):S103.
  • A genome-scale CRISPR tool for targeting multiple gene family members at once. Nat Plants. 2023 Apr;9(4):511-512. doi: 10.1038/s41477-023-01388-y. No abstract available. PubMed 36973416 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because data sharing is not planned for this study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for May 2027, 16 months later.

Of 45 non-industry phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 16 months is below that.

Counting every sponsor, half of 155 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 22, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07297069
Responsible party
Mohan Ramchandani (Senior Registrar, Asian Institute of Gastroenterology, India) — Principal investigator
First posted
Dec 22, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 24, 2025

Study contacts

Vamsi Krishna Ankam, DrNB(medical gastroenterology)
Contact
Vamsiankam999@gmail.com
+91 9705904243
Pardhu Bharath Neelam, DM (gastroenterology)
Contact
Drpardhu.bharath@gmail.com
+91 7799456166
Vamsi Krishna Ankam, DrNB(gastroenterology)
principal investigator · Asian Institute of Gastroenterology, Hyderabad

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Infliximab · Tofacitinib

Start the discussion